Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Granger

Showing results (901-910 of 1,023) with videos related to

Pageof 103
Sort By:
Blood|March 31, 2017
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapyRenato D Lopes, Patrícia O Guimarães, Bradley J Kolls, et al.
Circulation|March 23, 2005
Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot TrialShamir R Mehta, Philippe Gabriel Steg, Christopher B Granger, et al.
JAMA Cardiology|August 7, 2024
Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI TrialsJames P Curtain, Marc A Pfeffer, Eugene Braunwald, et al.
International Journal of Cardiology|February 12, 2013
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudySean van Diepen, L Kristin Newby, Renato D Lopes, et al.
Circulation|October 29, 2008
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trialsShamir R Mehta, William E Boden, John W Eikelboom, et al.
Journal of the American College of Cardiology|August 3, 2019
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection FractionJasper Tromp, Li Shen, Pardeep S Jhund, et al.
Circulation|August 3, 2016
Regional Systems of Care Demonstration Project: American Heart Association Mission: Lifeline STEMI Systems AcceleratorJames G Jollis, Hussein R Al-Khalidi, Mayme L Roettig, et al.
American Heart Journal|January 5, 2021
Risk markers of incident atrial fibrillation in patients with coronary heart diseaseMaria Tomasdottir, Claes Held, Nermin Hadziosmanovic, et al.
JAMA Cardiology|May 25, 2022
Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS TrialM Cecilia Bahit, Amit N Vora, Zhuokai Li, et al.
Circulation|October 20, 2004
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trialsJames B Young, Mark E Dunlap, Marc A Pfeffer, et al.
Pageof 103

Showing results (901-910 of 1,023) with videos related to

Sort By:
Pageof 103
Blood|March 31, 2017
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapyRenato D Lopes, Patrícia O Guimarães, Bradley J Kolls, et al.
Circulation|March 23, 2005
Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot TrialShamir R Mehta, Philippe Gabriel Steg, Christopher B Granger, et al.
JAMA Cardiology|August 7, 2024
Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI TrialsJames P Curtain, Marc A Pfeffer, Eugene Braunwald, et al.
International Journal of Cardiology|February 12, 2013
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudySean van Diepen, L Kristin Newby, Renato D Lopes, et al.
Circulation|October 29, 2008
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trialsShamir R Mehta, William E Boden, John W Eikelboom, et al.
Journal of the American College of Cardiology|August 3, 2019
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection FractionJasper Tromp, Li Shen, Pardeep S Jhund, et al.
Circulation|August 3, 2016
Regional Systems of Care Demonstration Project: American Heart Association Mission: Lifeline STEMI Systems AcceleratorJames G Jollis, Hussein R Al-Khalidi, Mayme L Roettig, et al.
American Heart Journal|January 5, 2021
Risk markers of incident atrial fibrillation in patients with coronary heart diseaseMaria Tomasdottir, Claes Held, Nermin Hadziosmanovic, et al.
JAMA Cardiology|May 25, 2022
Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS TrialM Cecilia Bahit, Amit N Vora, Zhuokai Li, et al.
Circulation|October 20, 2004
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trialsJames B Young, Mark E Dunlap, Marc A Pfeffer, et al.
Pageof 103